Covaxin approval: Beyond the emotional outburst, here’s what Bharat Biotech’s Krishna Ella said about the vaccine

The approval of Covaxin, which is still undergoing phase-3 clinical trials and yet to have efficacy data, has been roundly criticised. But Krishna Ella, Chairman and Managing Director of Bharat Biotech, the maker of Covaxin, feels a lot of that criticism is not justified. Here’s a look at what he had to say about its efficacy and immunogenicity data, administering it in ‘clinical trial mode’ and whether it is just a ‘back-up’ vaccine